Choosing between stem cell therapy and drugs in myelofibrosis

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

“…Non-HCT modalities may improve symptoms and stabilize the disease for variable periods of time; however, with this approach, patients are probably offered HCT, the only curative therapy for myelofibrosis, at a more advanced stage of their disease, when outcome is expected to be inferior to what could have been achieved with an earlier HCT. 38 As we expect additional new treatment options to be developed, it will be increasingly important to integrate parameters of prognostic relevance into both the HCT and non-HCT settings. Therefore, we sought to determine the impact of the DIPSS, widely used to counsel patients with myelofibrosis, on post-HCT outcomes.…”

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study

“…[5][6][7][8] Splenectomy is indicated in patients with symptoms related to splenomegaly, but the role of splenectomy before allogeneic transplantation is unclear. Although splenomegaly has been associated with prolonged time to engraftment, studies to date have not shown any consistent difference in transplantation outcomes in splenectomized patients 9,10 and splenectomy in CIMF patients has been associated with a high rate of complications.…”

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

“…[2][3][4] Conventional treatment is ineffective; stem cell transplantation is reserved for younger patients with dismal outcome, 5 as those included in intermediate-2 (projected survival, 4-5 years) or high-risk (2-2.5 years) category of IPSS or DIPPS-plus prognostic scores. [6][7][8] Activating mutations in JAK2, MPL, and calreticulin are found in @60%, 8%, and 15% to 25% of PMF patients, respectively.…”